ArticlePloS one2013
A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Advances in Decoding Bacterial N-Terminal Proteoforms: Technologies, Challenges, and Functional Insights.Microorganisms · 2026Review
- Mass spectrometry proteomics for studying mitostasis.Protein science : a publication of the Protein Society · 2026Review
- Gene expression flux analysis reveals specific regulatory modalities of gene expression.iScience · 2023Article
- N-terminal acetylation can stabilize proteins independent of their ubiquitination.Scientific reports · 2023Article
- Finding a vocation for validation: taking proteomics beyond association and location.RSC chemical biology · 2023Review
- Spatial Stable Isotopic Labeling by Amino Acids in Cell Culture: Pulse-Chase Labeling of Three-Dimensional Multicellular Spheroids for Global Proteome Analysis.Analytical chemistry · 2021Article
- Quantitative analysis of global protein stability rates in tissues.Scientific reports · 2020Article
- Site-Specific Protein Labeling with Fluorophores as a Tool To Monitor Protein Turnover.Chembiochem : a European journal of chemical biology · 2020Article
- Systematic quantification of the dynamics of newly synthesized proteins unveiling their degradation pathways in human cells.Chemical science · 2020Article
- ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer.Oncotarget · 2019Article
- HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving NNature communications · 2019Article
- The first Autumn School on Proteostasis: from molecular mechanisms to organismal consequences.Cell stress & chaperones · 2019Article
- Pulsed SILAC-based proteomic analysis unveils hypoxia- and serum starvation-inducedOncotarget · 2019Article
- Peptide Level Turnover Measurements Enable the Study of Proteoform Dynamics.Molecular & cellular proteomics : MCP · 2018Article
- Proteomic interrogation of HSP90 and insights for medical research.Expert review of proteomics · 2017Review
- Simultaneous Quantitation of Glycoprotein Degradation and Synthesis Rates by Integrating Isotope Labeling, Chemical Enrichment, and Multiplexed Proteomics.Analytical chemistry · 2017Article
- Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates.Pharmacology research & perspectives · 2017Article
- pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4Nature communications · 2017Article
- Positional proteomics reveals differences in N-terminal proteoform stability.Molecular systems biology · 2016Article
- Systematic study of the dynamics and half-lives of newly synthesized proteins in human cells.Chemical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard proteomics methods allow the relative quantitation of levels of thousands of proteins in two or more samples. While such methods are invaluable for defining the variations in protein concentrations which follow the perturbation of a biological system, they do not offer information on the mechanisms underlying such changes. Expanding on previous work [1], we developed a pulse-chase (pc) variant of SILAC (stable isotope labeling by amino acids in cell culture). pcSILAC can quantitate in one experiment and for two conditions the relative levels of proteins newly synthesized in a given time as well as the relative levels of remaining preexisting proteins. We validated the method studying the drug-mediated inhibition of the Hsp90 molecular chaperone, which is known to lead to increased synthesis of stress response proteins as well as the increased decay of Hsp90 "clients". We showed that pcSILAC can give information on changes in global cellular proteostasis induced by treatment with the inhibitor, which are normally not captured by standard relative quantitation techniques. Furthermore, we have developed a mathematical model and computational framework that uses pcSILAC data to determine degradation constants kd and synthesis rates Vs for proteins in both control and drug-treated cells. The results show that Hsp90 inhibition induced a generalized slowdown of protein synthesis and an increase in protein decay. Treatment with the inhibitor also resulted in widespread protein-specific changes in relative synthesis rates, together with variations in protein decay rates. The latter were more restricted to individual proteins or protein families than the variations in synthesis. Our results establish pcSILAC as a viable workflow for the mechanistic dissection of changes in the proteome which follow perturbations. Data are available via ProteomeXchange with identifier PXD000538.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.